News
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Mar 26, 2018
Creative Medical Technology Holdings, Inc. (OTCQB-CELZ) will be exhibiting it's patented CaverStemTM stem cell procedure for erectile dysfunction at the annual American Urological Association...
-
Feb 20, 2018CerebroStem LLC to Develop Patented Stem Cell Approaches to Treat Brain Damage
Creative Medical Technology Holdings (OTCQB:CELZ) announced today the formation of CerebroStem LLC, a majority owned subsidiary focused on developing stem cell therapies for brain injuries and...
-
Dec 20, 2017
Creative Medical Technology Holdings, Inc (OTCQB:CELZ) provides the following discussion on a recent US News and World Report article[1] addressing advances of adult stem cells and its own...
-
Dec 18, 2017
Creative Medical Technology Holdings, Inc. (OTCQB ticker symbol CELZ) announced today initiation of patient treatments using its patented Caverstem™ procedure by Dr. Alexander Gershman. Dr....
-
Dec 14, 2017
Creative Medical Technology Holdings, Inc. (OTCQB ticker symbol CELZ) announced today recruitment of leading urologists in the Southwestern United States to perform its patented CaverstemTM...
-
Oct 19, 2017Trial Results Support Initiation of Urologist Outreach and Commercialization
Creative Medical Technology Holdings (OTCQB – CELZ) announced today completion of the safety data analysis on 20 patients with pharmacologically-resistant erectile dysfunction treated with the...
-
Oct 16, 2017Regenerative Medicine Company Files Patent on Practice of Medicine Procedure to Address Stroke
Creative Medical Technology Holdings (OTCQB: CELZ) announced today filing of a patent application using a combination of an FDA approved drug together with the patient's own bone marrow derived...
-
Aug 28, 2017Company on Schedule for 2018 Commercialization of its Patented CaverstemTM Procedure to Treat Erectile Dysfunction in Patients who do not Respond to Currently Available Treatments
Creative Medical Technology Holdings Inc. (OTCQB ticker symbol CELZ) announced today completion of enrollment in the Company's clinical trial assessing safety and efficacy of its CaverstemTM...
-
Jul 25, 2017Company's Unique Stem Cell Nanotechnology Approach Appears to Stimulate Regeneration of Healthy Brain Cells While Selectively Inhibiting Glioma Brain Cancer
Creative Medical Technology Holdings, Inc. (OTCQB:CELZ), a clinical stage stem cell company, announced preclinical data showing exosomes harvested from its patented AmnioStem amniotic fluid stem...
-
Jun 21, 2017Company Expands Intellectual Property Portfolio in Lower Back Pain Indication
Creative Medical Technology Holdings, Inc. (the "Company") (OTCQB:CELZ) announced the filing of intellectual property covering data supporting the use of immune system cells for stimulation of...
-
Jun 7, 2017Company files Patent to Increase Circulation around Stem Cell Implantation Sites to Improve Effects of Cellular Therapies
Creative Medical Technology Holdings, Inc. (OTCQB:CELZ) announced filing of a patent application covering synergy between intradiscal stem cell injection subsequent to stimulation of perispinal...
-
May 24, 2017Company Discovers Novel Method of Suppressing Inflammation Using Combination Autologous-Allogeneic System
Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) (the "Company") announced today the filing of a patent application covering a novel means of suppressing inflammation associated with...
-
May 18, 2017Clinical Stage Stem Cell Company Continues Aggressive Pursuit of Personalized, Rapid to Implement, Autologous Regenerative Medicine Procedures
Creative Medical Technology Holdings, Inc. (OTCQB:CELZ) announced today the acquisition of issued US patent #9,598,673 covering use of various stem cells for treatment of lower back pain through...
-
Apr 4, 2017Company Aims to Leverage Stem Cell Neuroregenerative Activity to Reduce Adverse Effects of Brain Radiation
Creative Medical Technology Holdings, Inc. (OTCQB:CELZ), a clinical stage stem cell company, announced today filing of a patent application covering the use of its AmnioStem Universal Donor stem...
-
Mar 8, 2017Clinical Stage Stem Cell Company to Accelerate Product Development Leveraging Experience of Dr. Thomas Ichim
Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) announced today the appointment of Dr. Thomas Ichim to the position of Chief Scientific Officer. Dr. Ichim will lead development of the...
-
Feb 22, 2017Clinical Stage Stem Cell Company Expands Translational Research Activities with Acceptance into Premier San Diego Research Facility
Creative Medical Technology Holdings (the "Company") (OTCQB:CELZ) announced today expansion of its translational research program using its AmnioStem universal donor stem cell product through...
-
Dec 13, 2016Collaboration between Stem Cell Clinician, Neurologist, and Cell Therapy Developer Results in Novel Regenerative Approach to Stroke
Creative Medical Technology Holdings (the "Company") (OTCQB:CELZ) announced today filing of US patent application #62/400557 entitled "Treatment of Stroke by Amniotic Fluid Derived Stem Cell...
-
Dec 6, 2016Clinical Stage Stem Cell Therapeutics Company Aims to Develop "Universal Donor" Stem Cell "Drug" for Stroke Patients
Creative Medical Technology Holdings (OTCQB:CELZ) announced the appointment of Santosh Kesari, MD, PhD, FANA, FAAN to the Company's Scientific Advisory Board. Dr. Kesari will leverage his...
-
Nov 16, 2016Clinical Stage Stem Cell Therapeutics Company Expands Regenerative Medicine Portfolio to 'Off-the-Shelf' Allogeneic Stem Cell Products
Creative Medical Technology Holdings (OTCQB:CELZ) announced today the formation of a wholly-owned subsidiary, AmnioStem LLC, focused on the development of therapeutic products derived from...
-
Nov 2, 2016Patent Rights Cover Multipotent Amniotic Fetal Stem Cells
Creative Medical Technology Holdings, Inc. (OTCQB:CELZ) announced today signing of an exclusive license agreement with the University of California System to commercialize and develop a novel type...
-
Nov 1, 2016Clinical Stage Company Developing Stem Cell Therapy for Treatment-Refractory Erectile Dysfunction Recruits "Doctor to the Stars"
Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) announced today appointment of Alexander Gershman, MD, Ph.D to the company's Scientific Advisory Board. Dr. Gershman is an...
-
Aug 24, 2016Company Files Patent on Rejuvenating Ovaries through Use of Endothelial Progenitor Cell Stem Cells
Creative Medical Technology Holdings, Inc. (OTCQB: CELZ) announced the filing of a patent application disclosing means of regenerating failing ovaries through use of a particular type of stem cell...
-
Jun 21, 2016Clinical Stage Erectile Dysfunction Company Expands Product Pipeline into Reproductive Immunology
Creative Medical Technologies (OTCQB: CELZ) announced today filing of a patent application containing novel data suggesting that specialized cells obtained from adipose (fat) tissue are capable of...